Holmes Biopharma, Inc. (LMB) Reports Q2 EPS of $0.09, Revenues Beat; Lifts FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Limbach Holdings Reports Second Quarter 2018 Results
August 14, 2018 4:15 PM EDTQ2 2018 Revenues up 18.4% Versus Prior Year; Aggregate Backlog of $492.5 million at Quarter End
Conference Call Scheduled for 9:00am ET Wednesday August 15, 2018
PITTSBURGH--(BUSINESS WIRE)-- Limbach Holdings, Inc. (NASDAQ: LMB) (Limbach or the Company) today announced financial results for the quarter ended June 30, 2018. Total Q2 2018 revenues increased 18.4% versus the prior year period to $139.5 million. Construction segment revenue grew 18.2% from the prior year period while Service segment revenues gained 19.3%.
Other key financial highlights of the quarter included:
Gross margin was 11.3% in the second... More